

Erratum to: Effect of simvastatin plus cetuximab/irinotecan for *KRAS* mutant colorectal cancer and predictive value of the *RAS* signature for treatment response to cetuximab

Jeeyun Lee · Yong Sang Hong · Jung Yong Hong · Se Won Han · Tae Won Kim · Hye Jin Kang · Tae You Kim · Kyu-pyo Kim · Suk Hyung Kim · In-Gu Do · Kyoung-Mee Kim · Insuk Sohn · Se Hoon Park · Joon Oh Park · Ho Yeong Lim · Yong Beom Cho · Woo Yong Lee · Seong Hyeon Yun · Hee Cheol Kim · Young Suk Park · Won Ki Kang

Published online: 20 September 2014
© Springer Science+Business Media New York 2014

Erratum to: Invest New Drugs (2014) 32:535–541
DOI 10.1007/s10637-014-0065-x

In the original version of this article, we have had unintentional mistakes for measuring progression-free survival (PFS). The corrected progression-free survival was 3.7 months (95% CI 2.1–5.3). So, we revised Table 3, Figure 2a, c and manuscript (Results section and Discussion section). We also added secondary endpoints which had been described in the study protocol according to the recommendation by the sponsor (Merck).

The online version of the original article can be found at <http://dx.doi.org/10.1007/s10637-014-0065-x>.

J. Lee · J. Y. Hong · S. H. Park · J. O. Park · H. Y. Lim · Y. S. Park · W. K. Kang (✉)
Division of Hematology-Oncology, Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, 50 Irwon-dong Gangnam-gu, Seoul 135-710, South Korea
e-mail: wkkang@skku.edu

Y. S. Hong · T. W. Kim · K.-p. Kim
Department of Oncology, Asan Medical Centre, University of Ulsan College of Medicine, Seoul, South Korea

S. W. Han · T. Y. Kim
Division of Medical Oncology, Department of Internal Medicine, Seoul National University Hospital, Seoul National University College of Medicine, Seoul, South Korea

Table 3 Response according to RECIST (version 1.1) and survival outcome

Response	Number of patients (%, 95% CI)
Complete response	0 (0)
Confirmed partial response	1 (1.9, -1.8-5.6)
Confirmed stable disease	33 (63.5, 50.4-76.6)
Progressive disease	13 (25.0, 13.2-36.8)
Not evaluable	5 (9.6, 1.6-17.6)
Disease control rate (CR + PR + SD)	34 (65.4, 52.5 -78.3)
Survival outcome	Months (95% CI)
Progression-free survival	3.7 (2.1-5.3)
3-month progression-free survival rate	55%
6-month progression-free survival rate	33%
1-year progression-free survival rate	0%
Overall survival – months	12.8 (9.5-16.2)
6-month overall survival rate	81%
1-year overall survival rate	65%

H. J. Kang
Division of Hematology/Oncology, Department of Internal Medicine, Korea Cancer Center Hospital, Korea Institute of Radiological and Medical Sciences, Seoul, South Korea

S. H. Kim · I.-G. Do · K.-M. Kim
Department of Pathology, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, South Korea

I. Sohn
Samsung Medical Center, Samsung Cancer Research Institute, Seoul, South Korea

Y. B. Cho · W. Y. Lee · S. H. Yun · H. C. Kim
Department of Surgery, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, South Korea




Fig. 2 a Progression-free survival b Overall survival c Overall survival according to codon 12 and codon 13 KRAS mutations